Welcome to our dedicated page for Liquidia Corporation SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Liquidia Corporation (NASDAQ: LQDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation focused on biopharmaceutical products for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD), Liquidia uses these filings to report financial results, material agreements, governance changes and other significant events.
Investors can review Forms 10‑K and 10‑Q for detailed discussions of Liquidia’s business, including its PRINT® technology platform, the commercialization of YUTREPIA™ (treprostinil) inhalation powder, development of the investigational L606 treprostinil liposome inhalation suspension, and promotion of generic Treprostinil Injection under a profit‑sharing agreement with Sandoz. These periodic reports typically include segment information, research and development spending, risk factors related to PAH and PH‑ILD markets, and descriptions of key contracts.
Current reports on Form 8‑K highlight specific events such as quarterly earnings releases, financing transactions under the revenue interest financing agreement with HealthCare Royalty Partners IV, L.P. (HCR), entry into the exclusive license with Vectura for the nebulizer device used with L606, leases for expanded manufacturing facilities in Morrisville, North Carolina, and outcomes of annual stockholder meetings. Other 8‑K filings may document executive appointments, compensation arrangements and other governance matters.
Users can also monitor proxy statements and Form 4 insider transaction reports to understand board elections, advisory votes on executive compensation and equity awards to officers and directors. Stock Titan’s interface combines these documents with AI‑powered summaries that explain complex sections of long filings, highlight key changes from prior periods and help clarify how new agreements, clinical developments or financing structures may affect Liquidia’s operations and capital structure.
With real‑time updates from EDGAR and structured access to historical filings, this page serves as a central resource for analyzing Liquidia’s regulatory history, capital markets activity and disclosures related to its treprostinil‑based therapies for PAH and PH‑ILD.
Michael Kaseta, Liquidia Corporation's CFO and COO, reported a sale of 20,000 shares of common stock on 08/15/2025 executed pursuant to a Rule 10b5-1 trading plan. The weighted average price for the transactions on that date was $26.1837 (prices ranged $25.80–$26.50). After the sale, the reporting person beneficially owned 356,412 shares, which include multiple unvested restricted stock unit grants from 2023–2025 and 10,417 shares purchased under the company ESPP. The Form 4 was filed by one reporting person and is signed by Mr. Kaseta.
Liquidia Corporation reported initial commercial sales following FDA approval of YUTREPIA and posted early-stage revenue while remaining loss-making. YUTREPIA was approved by the FDA on May 23, 2025 and commercially launched on June 2, 2025; product sales for the three months ended June 30, 2025 were $6.5 million and service revenue (from the Sandoz promotion agreement) was $2.3 million, producing total revenue of $8.8 million for the quarter and $12.0 million for the six months.
The company reported a net loss of $41.6 million for the quarter and $79.9 million for the six months, driving an accumulated deficit of $637.3 million. Cash and cash equivalents were $173.4 million and total assets were $257.4 million. Total liabilities rose to $242.2 million driven by long-term debt (carrying value $193.6 million) and litigation finance obligations. Stockholders' equity declined to $15.2 million. The company disclosed ongoing patent and related litigation with United Therapeutics that could affect YUTREPIA, an indemnification asset of $8.3 million and a litigation finance payable of $8.0 million. Management states available cash and anticipated YUTREPIA inflows are expected to satisfy obligations for at least the next twelve months, and the HCR revenue interest financing contains a $15.0 million minimum cash covenant.
Liquidia Corporation furnished a press release announcing its financial results for the quarter ended June 30, 2025 and provided a corporate update. The press release is attached to the Form 8-K as Exhibit 99.1, and the filing includes an Inline XBRL cover page file as Exhibit 104.
The disclosure in Item 2.02 is furnished rather than filed and therefore is not deemed filed under Section 18 of the Exchange Act. No financial figures, operational details or transaction terms are included in this 8-K itself; the substantive results and update are contained in the referenced press release.